Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

SISCAPA Assay Technologies Appoints Gustavo Salem as President and CEO

Published: Monday, April 28, 2014
Last Updated: Tuesday, April 29, 2014
Bookmark and Share
Gustavo has previously worked worked closely with the company to evaluate strategic opportunities in life science research.

SISCAPA Assay Technologies, Inc. today announced the appointment of Gustavo (Gus) Salem to the position of President and CEO.  For the past 18 months, Gus has served as a member of the board of directors and has worked closely with the company to evaluate strategic opportunities in the life science research and clinical diagnostics markets.

“We are extremely pleased to have Gus join the SAT team, and to drive our execution as a commercial stage company,” said Leigh Anderson, SAT’s founder, who continues as Chairman and Chief Scientific Officer.  “Gus has already brought great value as an engaged board member based on a proven track-record in building teams, developing strategy and entering new markets.  His familiarity with the company, technology and team will provide for a smooth and effective transition.”

Gus brings over 25 years of life science and health science leadership experience to the position. Previously, while VP and General Manager of the Biological Systems Division at Agilent Technologies, he managed the mass spectrometry, genomics, and clinical diagnostics businesses amounting to >$500M annual sales. During his tenure, Agilent developed into a market-leading supplier of LC/MS and established market leadership in target enrichment sample prep for next generation DNA sequencing. Gus previously served as President and CEO of Assay Designs, Inc., a venture-backed company developing immunoassays and antibody reagents (now part of Enzo Life Sciences). Prior to Assay Designs he managed the Protein Separations Division of Bio-Rad Laboratories, which included product lines for chromatography and electrophoresis instruments and consumables.

“I want to thank Leigh and my fellow board members for this opportunity.  We have identified some very exciting new diagnostic opportunities, and will continue to invest in the analytical and clinical validation of SISCAPA technology.  The company is committed to our current partners and customers in improving access to the technology, and expanding our customer base through launch of new products and services,” said Mr. Salem.  “I am very excited to lead the team as we increase our focus on lab operations and commercial activities.  We have great partners, strong revenue momentum, and an excellent strategy focused on empowering patients through improved clinical tests.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos